Lorem Vascular (Singapore)

Lorem Vascular (Singapore) is a Singapore-headquartered company operating in the field of regenerative medicine. According to its official website, the company was formed to capture opportunities in regenerative medicine across Australia, Singapore, Malaysia, Hong Kong and China, focusing on therapeutic areas including breast reconstruction, chronic wounds resulting from radiation or diabetes, erectile dysfunction, systemic scleroderma, osteoarthritis and sports injuries. Its stated mission is to improve human health and quality of life through regenerative medicine. The company's flagship offering is the Celution System, a closed and sterile cell separation system developed by Cytori Therapeutics, Inc. of the United States. The system isolates the stromal vascular fraction (SVF), also referred to as adipose-derived regenerative cells (ADRC), from lipoaspirates at the point of care. Lorem Vascular states that, among commercially available SVF or ADRC isolation systems, the Celution System obtains the highest mean number of viable nucleated cells, citing a 2013 head-to-head comparison published in Plastic and Reconstructive Surgery. Lorem Vascular positions itself as a commercialisation and distribution platform for regenerative medicine technologies in the Asia-Pacific region. Its website reports that its technology has helped more than 6,000 patients worldwide achieve a better quality of life, and it emphasises ease of use, clinical safety, relative economy and superior patient outcomes as differentiators. The company maintains a head office at 16 Raffles Quay, #10-00 Hong Leong Building, Singapore 048581, and lists additional locations in Beijing, China (China Life Tower, Chaoyang District) and in Malaysia (The Boulevard Offices, Mid Valley City). Its website functions primarily as a portal for enquiries rather than a full e-commerce or product catalogue site. As a corporate entity, Lorem Vascular (Singapore) is recorded in Wikidata as a company in Singapore. Public evidence does not disclose its founding year, founders, ownership structure or listing status, and the company appears to operate as a privately held commercialisation vehicle rather than a listed enterprise. Its business model centres on bringing established overseas regenerative medicine platforms — notably Cytori's Celution System — into selected Asian markets and supporting clinicians and patients in their use.

Lorem Vascular (Singapore) was formed to capture opportunities in the field of regenerative medicine across Australia, Singapore, Malaysia, Hong Kong and China. The company's official website states that it was established specifically to pursue these regional opportunities, with a focus on therapeutic applications including breast reconstruction, chronic wounds resulting from radiation or diabetes, erectile dysfunction, systemic scleroderma, osteoarthritis and sports injuries. The company's business is built around the Celution System, a closed and sterile cell separation system developed by Cytori Therapeutics, Inc. of the United States. The Celution System isolates the stromal vascular fraction (SVF) — also known as adipose-derived regenerative cells (ADRC) — from lipoaspirates at the point of care. Lorem Vascular describes the system as market-leading and states that, of all commercially available SVF or ADRC isolation systems, the Celution System obtains the highest mean number of viable nucleated cells, citing a 2013 head-to-head comparison of four commercial cell separation systems published in Plastic and Reconstructive Surgery by Aronowitz and Ellenhorn. By the time of its current website, Lorem Vascular reported that its technology had successfully helped more than 6,000 patients worldwide achieve a better quality of life. The company maintains a head office at 16 Raffles Quay, #10-00 Hong Leong Building, Singapore 048581, with additional listed locations in Beijing, China (China Life Tower, No. 16 Chaowai Street, Chaoyang District) and in Malaysia (5-9A The Boulevard Offices, Mid Valley City, Lingkaran Syed Putra). Public evidence does not disclose the company's founding year, founders, ownership structure or listing status. Wikidata records it simply as a company in Singapore. Its website serves primarily as a portal for enquiries rather than a full corporate or product information site, and the company appears to operate as a privately held commercialisation vehicle for regenerative medicine technologies in its target markets.

Commercialisation and distribution platform for regenerative medicine technologies in Asia-Pacific, emphasising ease of use, clinical safety, relative economy and superior patient outcomes.

• Celution System

  A closed and sterile cell separation system developed by Cytori Therapeutics, Inc. (U.S.A.) that isolates the stromal vascular fraction (SVF), also known as adipose-derived regenerative cells (ADRC), from lipoaspirates at the point of care.

1. 1Lorem Vascular | Lorem Vascularloremvascular.com
2. 2Lorem Vascular (Singapore) - Wikidatawikidata.org